Herbalife

HLF · NYSE

$13.39−$0.39 (−2.83%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $13.78

HLF analyst rating

BuyConsensus of 5 analysts over the last 12 months. 60% rate it a buy.

Strong buy0
Buy3
Hold2
Underperform0
Sell0

12-month price target · 5 analysts

Average $18.36 (+37.1% upside)

Low: $9.09
Now: $13.39
High: $26.25

Upgrades and downgrades

The latest rating actions, newest first

HLF analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citigroup	Aug 7, 2026	Maintains	Buy	$21.00 → $17.00	46%
RBC Capital	Apr 28, 2026	Maintains	Sector Perform	$17.00 → $16.00	43%
Mizuho	Mar 30, 2026	Maintains	Neutral	$13.00 → $15.00	50%
Citigroup	Feb 19, 2026	Maintains	Buy	$17.00 → $21.00	46%
Mizuho	Jan 8, 2026	Maintains	Neutral	$11.00 → $13.00	50%
Maxim Group	Jan 6, 2026	Initiates	Buy	$20.00	26%
Citigroup	Dec 12, 2025	Maintains	Buy	$11.00 → $17.00	46%
Mizuho	Nov 26, 2025	Maintains	Neutral	$10.00 → $11.00	50%
Argus Research	Nov 26, 2025	Upgrade	Hold → Buy	—	55%

The case for and against

Updated Oct 15, 2026

Bull case

Herbalife is showing early evidence that its margin recovery is gaining traction, with underlying Q2/26 adjusted EBITDA in line after normalizing for a $7.9MM IEEPA tariff refund and $10.1MM of fire-related inventory losses, while gross margin pressure eased sequentially. Management’s 2026 outlook for YoY adjusted EBITDA growth was reiterated, supported by a structural tariff tailwind as rates have fallen from high-teens to 10%-12.5%, plus pricing actions, more disciplined promotions, and SG&A held in the low-8% range of revenue. The outlook is further strengthened by expected H2/26 tariff refunds, ongoing cost-structure optimization, and a healthier balance sheet path, with net debt/adjusted EBITDA expected to move slightly below the 3.0x target by the end of 2026 absent refund benefits.

Bear case

Herbalife is facing a challenging operating backdrop marked by low consumer sentiment, inflationary pressure, tariffs, and elevated freight costs, which continue to weigh on margins and consumption despite management’s execution on distribution expansion, innovation, and selective M&A. Although Q2/26 revenue grew 12.4% year over year, supported by 4.0% volume growth and roughly 8.0% higher average selling prices, that pricing response reflects cost recovery rather than robust demand, and management still expects only low-single-digit volume growth for 2026. Even with improving gross margins, expected tariff refunds, and a path toward EBITDA margin recovery, the company remains vulnerable to further margin compression, making the outlook cautious.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.